000095793 001__ 95793
000095793 005__ 20210902121929.0
000095793 0247_ $$2doi$$a10.31083/J.EJGO.2020.04.8051
000095793 0248_ $$2sideral$$a120228
000095793 037__ $$aART-2020-120228
000095793 041__ $$aeng
000095793 100__ $$0(orcid)0000-0002-2378-8668$$aOrtega, S.$$uUniversidad de Zaragoza
000095793 245__ $$aThe impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer
000095793 260__ $$c2020
000095793 5060_ $$aAccess copy available to the general public$$fUnrestricted
000095793 5203_ $$aObjective: Analyze the effect on survival of secondary cytoreduction surgery (SCS) in treatment of first recurrence platinumsensitive epithelial ovarian cancer (REOC).
Methods: Retrospective analysis of patients with first REOC who had platinum timefree interval (TFIp) > 6 months and were treated either with SCS followed by chemotherapy or chemotherapy only (CT). Clinical data such as patient’s performance status and number of sites with metastases were specifically assessed. The primary endpoint was overall survival (OS).
Results: Seventyone patients were treated either by SCS (n = 37) or CT (n = 34). Complete resection after SCS was achieved in 89% of patients. After a median followup of 51.2 months, median OS, and progressionfree survival (PFS) were 68.2 and 21.6 months, respectively, for the whole series of the SCS patients had better survival and disease progression survival than the CT only patients (HR: 0.33, 95%CI: 0.170.6; p= 0.001) and (HR: 0.28, 95%CI: 0.150.5; p= 0.001), respectively. TFIp < 12 months and multiple metastases were most important prognostic factors for risk of death (HR: 7.7 and 6.2, respectively) and recurrence (HR: 5.8 and 3.8, respectively). Probability to undergo successful SCS is related to oligometastatic disease and no residual disease after first surgery (OR: 30.0 and 5.9, respectively).
Conclusions: In women with REOC oligometastatic disease and no residual disease at first surgery are associated with successful SCS. In these patients oligometastatic disease and long platinum TFI are associated with improved probability of survival.
000095793 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000095793 590__ $$a0.196$$b2020
000095793 591__ $$aONCOLOGY$$b240 / 242 = 0.992$$c2020$$dQ4$$eT3
000095793 591__ $$aOBSTETRICS & GYNECOLOGY$$b81 / 83 = 0.976$$c2020$$dQ4$$eT3
000095793 592__ $$a0.15$$b2020
000095793 593__ $$aOncology$$c2020$$dQ4
000095793 593__ $$aObstetrics and Gynecology$$c2020$$dQ4
000095793 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000095793 700__ $$aMínguez, J.A.
000095793 700__ $$aAramendía, J.M.
000095793 700__ $$aSantisteban, M.
000095793 700__ $$aMartinezRegueira, F.
000095793 700__ $$aMartí-Cruchaga, P.
000095793 700__ $$aAlcázar, J.L.
000095793 700__ $$aJurado, M.
000095793 7102_ $$11013$$2090$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Cirugía
000095793 773__ $$g41, 4 (2020), 523-530$$pEur. j. gynaecol. oncol.$$tEUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY$$x0392-2936
000095793 8564_ $$s167700$$uhttps://zaguan.unizar.es/record/95793/files/texto_completo.pdf$$yVersión publicada
000095793 8564_ $$s619617$$uhttps://zaguan.unizar.es/record/95793/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000095793 909CO $$ooai:zaguan.unizar.es:95793$$particulos$$pdriver
000095793 951__ $$a2021-09-02-10:53:41
000095793 980__ $$aARTICLE